Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00396383 · OUTCOME

Number of Transplantations That Achieved Polymorphonuclear Leukocyte (PMN) Engraftment Grouped by Days to Engraftment

Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and for Transplantation · Source last updated 2014-03-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
transplantations
Interval / dispersion
Not reported
Time frame
Approximately 2 months

What was measured

Polymorphonuclear cell (PMN) engraftment was defined as a PMN count ≥ 0.5\*10\^9/L for 3 consecutive days or ≥ 1\*10\^9/L for 1 day. Days to engraftment corresponded to the first day that the criteria were met after transplantation.

Analysis population: Intent to treat population includes participants who received plerixafor and underwent transplantation. One participant had two transplants.

Groups in this outcome

Participants With Multiple Myeloma (MM)

Participants with MM who were eligible for autologous peripheral blood stem cell transplantation were given 240 µg/kg daily subcutaneous plerixafor for up to 4 days.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Participants With Multiple Myeloma (MM)9

Analysis denominator · transplantations

GroupSource count
Participants With Multiple Myeloma (MM)10

Reported measurements

<= Day 12 post transplant
Values in transplantations · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Participants With Multiple Myeloma (MM)10Not reportedNot reportedNot reportedNot reported
Day 13 to 21 post transplant
Values in transplantations · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Participants With Multiple Myeloma (MM)0Not reportedNot reportedNot reportedNot reported
>= Day 22 post transplant
Values in transplantations · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Participants With Multiple Myeloma (MM)0Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        10
    title
    <= Day 12 post transplant
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        0
    title
    Day 13 to 21 post transplant
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        0
    title
    >= Day 22 post transplant
denom Units Selected
Participants
denoms
  1. counts
    1. group Id
      OG000
      value
      9
    units
    Participants
  2. counts
    1. group Id
      OG000
      value
      10
    units
    transplantations
description
Polymorphonuclear cell (PMN) engraftment was defined as a PMN count ≥ 0.5\*10\^9/L for 3 consecutive days or ≥ 1\*10\^9/L for 1 day. Days to engraftment corresponded to the first day that the criteria were met after transplantation.
groups
  1. description
    Participants with MM who were eligible for autologous peripheral blood stem cell transplantation were given 240 µg/kg daily subcutaneous plerixafor for up to 4 days.
    id
    OG000
    title
    Participants With Multiple Myeloma (MM)
param Type
NUMBER
population Description
Intent to treat population includes participants who received plerixafor and underwent transplantation. One participant had two transplants.
reporting Status
POSTED
time Frame
Approximately 2 months
title
Number of Transplantations That Achieved Polymorphonuclear Leukocyte (PMN) Engraftment Grouped by Days to Engraftment
type
SECONDARY
type Units Analyzed
transplantations
unit Of Measure
transplantations

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice